高盛最新研报以“2Q25 EPS更新”为主题其中重点对Amylyx(AMLX.US)、CG Oncology(CGON.

智通财经
Aug 12
高盛最新研报以“2Q25 EPS更新”为主题其中重点对Amylyx(AMLX.US)、CG Oncology(CGON.US)、硕迪生物(GPCR.US)、Ideaya生物科学(IDYA.US)等生物科技公司进行逐一拆解结论是:运营数据大体符合预期投资逻辑无需大改但个别公司因现金流或临床节点微调目标价。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10